article thumbnail

Ebola experimental vaccine trial may begin soon in Uganda

STAT

A clinical trial of one or perhaps two experimental vaccines designed to protect against the Ebola Sudan virus could soon begin in Uganda, as long as the country agrees to allow the research to take place, an official of the World Health Organization said Wednesday. Read the rest…

Vaccines 142
article thumbnail

ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial

Pharmafile

ILiAD Biotechnologies has announced that it has selected Emmes Group to conduct the upcoming phase 3 trials of its lead pertussis vaccine candidate, BPZE1. The two companies are currently working to finalise a definitive agreement for the collaboration.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Guaranteeing resilience in vaccine manufacturing

European Pharmaceutical Review

There has been a steady stream of developments in the vaccine manufacturing space throughout 2023. A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre.

article thumbnail

Data hackathon analyses truth behind TB vaccine and COVID-19

pharmaphorum

Is a century-old vaccine a ‘game-changer’ for COVID-19? Anita de Waard from Elsevier and Radoslav Kirkov from Estafet tells us how a hackathon is harnessing data science to look beyond the hype and seek definitive clinical evidence. This is especially true in the search for effective therapies to fight COVID-19, and a vaccine.

Vaccines 110
article thumbnail

What HCPs think about blood clots linked to COVID-19 vaccines

pharmaphorum

In the latest edition of What HCPs Think , CREATION.co’s Laura Marsh looks at what healthcare professionals are saying about blood clots linked to COVID-19 vaccines. This sudden increase is due to reports of rare blood clots in recipients of the COVID-19 vaccines developed by AstraZeneca and more recently Johnson & Johnson.

Vaccines 105
article thumbnail

Mankind Pharma acquires Bharat Serums and Vaccines for $1.6bn

Pharmaceutical Technology

Mankind Pharma has announced a definitive agreement for the acquisition of Bharat Serums and Vaccines (BSV) for Rs136.3bn ($1.6bn).

article thumbnail

Health Canada accepts Pfizer Canada’s bivalent RSV vaccine for review

Pharmaceutical Technology

Health Canada has accepted Pfizer Canada’s new drug submission for a bivalent respiratory syncytial virus (RSV) vaccine for review. The vaccine will be used to prevent lower respiratory tract disease and severe lower respiratory tract disease caused by RSV in adults aged 60 and above.